Abstract
The 2012/13 influenza season in Canada has been characterised to date by early and moderately severe activity, dominated (90%) by the A(H3N2) subtype. Vaccine effectiveness (VE) was assessed in January 2013 by Canada's sentinel surveillance network using a test-negative case-control design. Interim adjusted-VE against medically attended laboratory-confirmed influenza A(H3N2) infection was 45% (95% CI: 13-66). Influenza A(H3N2) viruses in Canada are similar to the vaccine, based on haemagglutination inhibition; however, antigenic site mutations are described in the haemagglutinin gene.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antigens, Viral / analysis
-
Canada / epidemiology
-
Case-Control Studies
-
Child
-
Child, Preschool
-
Female
-
Hemagglutination Inhibition Tests
-
Humans
-
Influenza A Virus, H3N2 Subtype / genetics
-
Influenza A Virus, H3N2 Subtype / immunology
-
Influenza A Virus, H3N2 Subtype / isolation & purification*
-
Influenza Vaccines / administration & dosage*
-
Influenza Vaccines / immunology
-
Influenza, Human / diagnosis
-
Influenza, Human / epidemiology*
-
Influenza, Human / prevention & control*
-
Influenza, Human / virology
-
Male
-
Middle Aged
-
Nasopharynx / virology
-
Nose / virology
-
Physicians, Family
-
Polymerase Chain Reaction
-
Sentinel Surveillance*
-
Sequence Analysis, DNA
-
Treatment Outcome
Substances
-
Antigens, Viral
-
Influenza Vaccines